Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.
Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, Milan, Italy.
Eur J Clin Invest. 2021 Jul;51(7):e13535. doi: 10.1111/eci.13535. Epub 2021 Mar 16.
HER2-positive (HER2+) breast cancer represents a heterogeneous breast cancer subtype, including both oestrogen receptor (ER) positive and negative tumours. A deeper understanding of the crosstalk between ER and HER2 receptor pathways has led to the development of treatment strategies consisting of a simultaneous blockade of both signalling pathways, as a reasonable approach to prevent the onset of mechanisms of resistance.
This review was based on the material searched on PubMed, MEDLINE and Embase databases and on conference proceedings from major oncology conferences up to 15 December 2020. The search strategy included the following keywords: 'HER2-positive breast cancer', 'CDK4-6 inhibitors' and 'PI3K inhibitors', and was adapted for use with different bibliographic databases.
CDK4/6 and PI3K inhibitors are two classes of agents already approved in patients with hormone receptor positive, HER2-negative breast cancer. Recently, promising data with their use have been also shown in HER2+ disease. Results from preclinical and clinical studies are shedding light on the role of these classes of agents in HER2+ breast cancer, and are paving the road for a forthcoming change in clinical practice.
Treatment landscape for HER2+ breast cancer is rapidly changing, and CDK4/6 and PI3K inhibitors represent a new promising strategy to improve patients' outcomes.
人表皮生长因子受体 2 阳性（HER2+）乳腺癌是一种异质性乳腺癌亚型，包括雌激素受体（ER）阳性和阴性肿瘤。对 ER 和 HER2 受体途径相互作用的深入了解，促使人们开发了同时阻断这两条信号通路的治疗策略，这是预防耐药机制发生的合理方法。
本综述基于截至 2020 年 12 月 15 日在 PubMed、MEDLINE 和 Embase 数据库中以及主要肿瘤会议的会议记录中搜索的材料。检索策略包括以下关键词：“HER2 阳性乳腺癌”、“CDK4-6 抑制剂”和“PI3K 抑制剂”，并针对不同的文献数据库进行了调整。
CDK4/6 和 PI3K 抑制剂是两种已在激素受体阳性、HER2 阴性乳腺癌患者中获批的药物。最近，在 HER2+疾病中也显示出了这些药物使用的有前景的数据。来自临床前和临床研究的结果揭示了这些药物类别在 HER2+乳腺癌中的作用，并为即将改变临床实践铺平了道路。
HER2+乳腺癌的治疗格局正在迅速变化，CDK4/6 和 PI3K 抑制剂代表了改善患者预后的一种新的有前途的策略。
